NAD+ Combinations: What the Research Says About Stacking

What Is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, functioning as an essential electron carrier in cellular redox reactions and as a substrate for enzymes involved in DNA repair, gene expression, and metabolic regulation. A 2018 review published in Advances in Food and Nutrition Research described it as central to maintaining cellular metabolism and respiration, alongside its phosphorylated form NADP+. The compound is distinct from its dietary precursors — niacin, NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside) — which the body converts into NAD+ through separate biosynthetic pathways. Research results from NMN or NR studies describe those precursors, not NAD+ itself.

---

What Is NAD+ Studied For?

Research on NAD+ goes back to 2018 — 8 years — with studies continuing through 2025.

1. Cellular Senescence Attenuation — A 2025 preclinical study published in ACS Nano engineered a nanoparticle delivery system designed to recycle intracellular NAD+ in aged mouse cells, reporting reductions in senescence-associated markers including inflammatory secretions and mitochondrial dysfunction.

2. Osteoarthritis and Joint Tissue — A separate 2025 ACS Nano preclinical study loaded NAD+ into lubricated hydrogel microspheres and administered them intra-articularly in a rodent model of age-related osteoarthritis, finding the approach addressed chondrocyte senescence, synovial inflammation, and joint lubrication simultaneously.

3. Skin Aging and CD38 Modulation — A 2024 human observational study examined the pharmacological activity of exogenous NAD+ in skin tissue, finding that degradation by the enzyme CD38 limited bioavailability, and that synergistic inhibition of CD38 expression enhanced the compound's effects on aging-related skin markers.

4. Physical Performance and Erythrocyte Levels — A 2024 human observational study of athletes found that systematic sports participation was associated with elevated erythrocyte NAD+ concentrations compared to sedentary controls, suggesting exercise as a physiological modulator of NAD+ status.

5. Developmental Biology and Congenital Disease Modeling — A 2025 preclinical study used a zebrafish model to examine how NAD+ deficiency during embryonic development produces congenital malformations across cardiac, renal, vertebral, and limb systems, establishing an animal framework for studying NAD+ deficiency disorder.

---

How Does NAD+ Work at the Cellular Level?

NAD+ functions in two mechanistically distinct roles. As a redox cofactor, it accepts and donates electrons in metabolic pathways including glycolysis, the tricarboxylic acid cycle, and the electron transport chain — processes that generate cellular energy. A 2018 methods paper in Antioxidants & Redox Signaling developed quantitation protocols for the full NAD+/NADH and NADP+/NADPH redox pairs, underscoring that the ratio of oxidized to reduced forms reflects real-time cellular metabolic state.

The second role is catalytic substrate. Enzymes including sirtuins (deacylases) and PARPs (DNA repair enzymes) consume NAD+ as a reactant, cleaving it during each catalytic cycle. This consumption-based demand means that sustained enzymatic activity depends on continuous NAD+ replenishment. A 2024 human observational study in Cells identified CD38 — a hydrolase expressed in immune and stromal cells — as a primary degradation route that limits how much exogenous NAD+ actually reaches intracellular targets, a finding with direct relevance to any combination strategy aimed at extending bioavailability.

---

What Does Animal Research Show About NAD+ Stacking Approaches?

Most experimental work combining NAD+ with other agents has been conducted in preclinical models, where researchers can control delivery routes and tissue targeting precisely.

The 2025 ACS Nano osteoarthritis study is the clearest example of a multi-component approach. Researchers embedded NAD+ within hydrogel microspheres that also provided lubrication to the joint surface — effectively pairing the compound's metabolic effects with a mechanical intervention. In aged rodents, this combination reduced chondrocyte senescence markers, attenuated synovial inflammation, and improved lubrication metrics simultaneously. The authors reported that no single component alone achieved all three outcomes, framing the combination architecture as the operative variable.

A second 2025 ACS Nano preclinical study took a different angle. Rather than combining NAD+ with a distinct pharmacological agent, the research group engineered a nanoparticle carrier that recycled intracellular NAD+ — essentially pairing the compound with a delivery mechanism designed to prevent its rapid degradation. The system targeted senescent cells specifically in aged mice and reduced the senescence-associated secretory phenotype (SASP) more effectively than unencapsulated NAD+. The implication is that delivery format itself functions as part of any effective NAD+ combination.

A 2025 zebrafish preclinical study focused not on stacking for enhancement but on rescue: supplementing NAD+ biosynthesis pathway intermediates in embryos with genetic deficiencies partially attenuated the severity of congenital malformations. This work establishes that the compound interacts with the broader biosynthetic network — niacin, NMN, NR — rather than acting in isolation.

---

What Does Human Research Show?

Human data directly examining NAD+ combinations is limited in size and scope. Two studies in the pool provide relevant human-level evidence, and neither was designed as a controlled trial of a stacking protocol.

A 2024 human observational study published in Cells (sample size not reported in the abstract) examined whether inhibiting CD38 alongside exogenous NAD+ administration could improve the compound's pharmacological reach in skin tissue. The study found that CD38 is a dominant degradation enzyme and that its suppression amplified downstream NAD+-dependent signaling. The researchers characterized this as a synergistic approach — not simply additive — because CD38 inhibition changed the effective concentration curve of NAD+ at the intracellular level. This study is notable because it frames a combination target based on degradation biology rather than additive benefit. The human observational design limits causal inference, and no sample size was disclosed.

A 2024 human observational study in BMC Sports Science, Medicine & Rehabilitation measured erythrocyte NAD+ concentrations across groups of athletes with different training histories. The study found that endurance-trained individuals showed higher NAD+ levels than power athletes or sedentary controls, pointing to aerobic exercise as a modulator of NAD+ status. Though not a combination or stacking study in the pharmacological sense, the finding suggests that exercise and NAD+ interact physiologically — a form of combination relevant to researchers studying metabolic outcomes.

A small open-label study (n=3) published in Endocrine Journal (2024) examined long-term NMN supplementation in healthy, middle-aged Japanese men and tracked changes in NAD+ biosynthesis alongside metabolic and sleep outcomes. Because this study examined NMN — a precursor, not NAD+ itself — its findings describe NMN's effects on the NAD+ biosynthesis pathway, not exogenous NAD+ administration. The distinction matters for stacking research: precursor-based and direct-supplementation approaches differ mechanistically, and the two should not be treated as equivalent.

---

What Is Still Unknown About NAD+ Combinations?

Several gaps limit what the current evidence base can support. No controlled human trial has tested a defined NAD+ stacking protocol — pairing the compound with CD38 inhibitors, sirtuin activators, or other agents — with pre-registered endpoints and adequate sample sizes. The human observational findings on CD38 inhibition and exercise-linked NAD+ elevation are hypothesis-generating, not confirmatory.

Bioavailability remains the central unresolved challenge. The 2025 preclinical work in ACS Nano addressed this directly by engineering delivery systems that protect NAD+ from extracellular degradation and promote intracellular uptake — problems that persist in any oral or systemic administration context. The same research group noted that without targeted delivery, the compound is unstable and cell-impermeant, which constrains any combination study that assumes the base compound is reaching its intracellular targets.

The relationship between precursor-based strategies (NMN, NR, niacin) and direct NAD+ administration in combination contexts is also unexplored at the human level. A 2018 review in Advances in Food and Nutrition Research described niacin-derived NAD+ as essential to metabolism and DNA repair, but whether precursor supplementation and exogenous NAD+ produce distinct or redundant effects when combined has not been tested in human trials. Zebrafish developmental research suggests the biosynthetic network is flexible and responsive to multiple inputs, but translating that model to human adult biology requires separate study.

Tissue specificity is a further open question. The osteoarthritis study targeted a joint compartment directly; the skin aging study examined dermal tissue. Whether systemic NAD+ administration reaches the tissues most relevant to any given research question — and whether a companion agent changes that distribution — has not been characterized in human subjects.

---

Where Can I Buy NAD+?

NAD+ is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---

---